Dr Julianna Lisziewicz, president of Genetic Immunity gave a Plenary Lecture at the 2nd Europe INNOVA Conference
Dr Julianna Lisziewicz, president of Genetic Immunity gave a Plenary Lecture at the 2nd Europe INNOVA Conference is organized by the French Presidency of the European Union in close collaboration with the European Commission (DG Enterprise & Industry) and hosted by the city of Lyon. The conference addressed policy priorities for accelerating innovation in Europe with particular focus on the role of research-driven innovation and knowledge transfer, the role of strategic partnerships in strengthening industry's innovation capacity and the mechanisms for supporting innovative SMEs and entrepreneurs. Go to homepage of INNOVA Conference... or Download the presentation (in PDF format)
July 13, 2008
Genetic Immunity to Present at 2008 BIO International Convention
Full viral suppression newest trend seen in the "post-HAART" era
New immunotherapy treatment could help with trend. In what might be called the post-HAART era, there is an encouraging new trend of clinicans seein greater numbers of patients who have undetectable viral lodas, according to an HIV clinican who has been in the trenches for over two decades. (Continued here...)
April 18, 2008
GI Published Data Related to the DermaVir NanomMedicine Patch in the Journal of Immunology
Genetic Immunity Published Data Related to the DermaVir Nanomedicine Patch in the Journal of Immunology: Data Supports Use of HIV-specific T cell Precursors with High Proliferative Capacity (PHPC) Marker to Predict Reduction of Viral Load. Blood cells from 32 participants were evaluated via a novel PHPC assay as well as a ELISPOT assay to determine which responses correlate with viral suppression and positive immunologic outcomes. The study indicated that a high magnitude of HIV-specific T cell Precursors with High Proliferative Capacity (PHPC), rather than ELISPOT responses, significantly correlated with low plasma viral loads and is therefore an effective diagnostic measurement for determining which responses correlate with viral suppression and positive immunologic outcomes. In contrast to PHPC, which identifies precursor T-cells with high proliferative capacity, ELISPOT is commonly used to monitor immune responses in humans and animals by identifying effector T-cells with low proliferative capacity.
January 24 2008 Genetic Immunity inaugurated its new office and laboratory facility located in Budapest Berlini street... Dr. Lisziewicz the CEO of Genetic Immunity noted the journey of the project during the past 10 years “from the Berlin Patient to the Berlin street”. Genetic Immunity has developing immune therapies inspired by an exceptional clinical observation of the Berlin Patient (Lisziewicz at al. New England Journal of Medicine 1999). The facility is the new home for chemistry, biology and molecular biology laboratories required for research and immune therapy product development. DermaVir Patch quality assurance and control studies will also be performed here in the qualified laboratories and product will be released worldwide to clinical trials. Product and clinical development process is supported by an experienced bio-Information Technology (bio-IT) team, a structure what is unique in this emerging biopharmaceutical industry. The office facility is the center for the Company’s executive management team as well as the international clinical development team.
January 22, 2008
GI on BioData Forum in Geneva
Zsolt Lisziewicz, Chief Operating Officer of Genetic Immunity is invited as speaker to the BioData Forum in Geneva (Visit website: www.biodataforum.com)
October 11, 2007
GI in the BioWorld Today
BioWorld Today: "Genetic Immunity LLC, of New York, has completed a $2 million bridge financing. Terms of the financing were not disclosed. The funds will be used to launch an additional Phase II proof-of-concept trial for the DermaVir Patch, the company's product for reconstituting the viral load in HIV-positive people."
September 28, 2007
"GlaxoSmithKline cancer vaccine 'impressive'" published by DrugResearcher.com
"Nanochemistry-Based Immunotherapy for HIV-1" is the new article of Prof. Julianna Lisziewicz. She is publishing in the Bentham Science Publishers. Download the article click here.
August 07, 2007
FDA approves new AIDS drug - can read the article on the USA Today webpage: www.usatoday.com
July 18, 2007
Dr. Julianna Lisziewicz, Chair of the Vaccine Therapy Cluster, is invited as speaker on the 15th International Congress of the Hungarian Society of Microbiology which will take place on July 18 - 20 in Budapest (Download: Program of Congress and Second Circular and General info. Or visit website: www.mmt.org.hu)
July 14, 2007
Quality scientific publications in Dermatology Open Journals (Bentham Scientific Publishers) See in details...
June 25, 2007
The European Commission has published the second FP7 call for proposals. Identifier: FP7-HEALTH-2007-B Publication date: 19 June 2007 Deadline: 18 September 2007 at 17:00:00 (Brussels local time) OJ Reference:OJ C135 of 19 June 2007 Additional information on the Health research call can be found under cordis.europa.eu
1st International Symposium on Genetic and Immune Correlates of HIV Infection and Vaccine-Induced Immunity 10-13 June, 2007. Budapest, Hungary. VTC (J. Lisziewicz) and Semmelweis University (G. Füst) are coorganizing the conference. For more information visit page www.hiv-correlates2007.hu
May 19, 2007
Interview on NPR with Dr. Anthony Fauci on the progress on prophylactic HIV vaccines Listen the interview here...
Article entitled "Magyarországra még vár a tudomány, de kire vár Magyarország?" has been published in magyaronline.net. Click here to read the article.
January 22, 2007
Recommendation of the Parliamentary Assembly of the Council of Europe: "...address the development and testing of medicines specifically for use in children living with HIV, and new technologies such as microbicides and HIV/AIDS vaccines" (click here...)
November 22, 2006
Intensive workshop on the project and on future progress of the atherosclerosis group (Programme)
November 10, 2006
On invitation of Prof. Julianna Lisziewicz Dr. Arya Suresh from USA visited us and held a successful seminar (Source)
In the monthly publication of Semmelweis University Kata Tolnai reported about the VTC cluster (source: Semmelweis Egyetem újság 2006/7.)
June 12, 2006
Dr. Julianna Lisziewicz, Chair of the Vaccine Therapy Cluster is invited as speaker to the AIDS Vaccine 2006 Conference which will take place on August 29 - September 1, 2006 in Amsterdam, The Netherlands. Her presentation title is "DermaVir patch therapeutic vaccine in chronic HIV infection: from the concept to the clinic". And the reaction:
June 12, 2006
Dr. Zsolt Lisziewicz, CEO of Genetic Immunity Kft. is invited to the Life Sciences Partnering China & Europe Programme which will take place on Sept. 18-19 in Beijing, China. Meetings with chinese vaccine development companies and leading CDC (Center of Desease Control) officers are planned as well.
June 12, 2006
Eszter Berzsenyi of Genetic Immunity starts one week visit to RIGHT Italy. She will work under the supervision of Prof. Franco Lori. The goal of her trip is to learn the biological assays characterizing the DermaVir Patch product and transfer these assays to the new Budapest laboratories of Genetic Immunity.
May 30, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited IATEC in Amsterdam to establish collaboration.
May 26, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited RIGHT to oversee the collaborative research progress between Genetic Immunity and RIGHT.
May 24, 2006
Prof. Julianna Lisziewicz, the leader of the Vaccine Therapy Cluster, has visited Karolinska Institute in Stockholm to establish collaboration.
May 17, 2006
The Second Management Committee Meeting took place in the Chemical Research Center, Budapest. There was discussion about the scientific progress, the patent and process development issues, ISO operating procedures. CRC team leaders presented excellent progress in vaccine chemistry. Leaders of VTC with Solvo defined the short, medium and long-term business development focus.
May 02, 2006
Dr. Eszter Ujhelyi of St Laszlo Hospital starts one week visit to RIGHT Italy. She will work under the supervision of Prof Franco Lori and Dr. Sandra Calarotta. The goal of her visit is to learn the ELISPOT and Cultured-ELISPOT assay and establish these assays in the clinical immune diagnostic laboratory of Laszlo Hospital.
